Jose G. Lazo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose G. Lazo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aashish Gupta
Ochsner Medical Center, New Orleans, Louisiana, USA
1 shared publication - Brandon Martinez
Department of Pharmacy, University of California San Francisco Health, San Francisco, CA 94143, USA
1 shared publication - Brandon Michael Henry
Clinical Laboratory, Division of Nephrology & Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
1 shared publication - Carl J. Lavie
John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA
1 shared publication - Catherine Nash
Department of Social Work, University of California San Francisco Health, San Francisco, CA 94143, USA
1 shared publication - Irina Yurkova
Department of Surgery, Division of Cardiothoracic Surgery, Section of Mechanical Circulatory Support, University of California San Francisco Health, San Francisco, CA 94143, USA
1 shared publication
Latest Publications
- Open Access
- 18 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1346
Care of Adult Heart Transplant Recipients by the Primary Care Provider: A Practical Roadmap
Heart transplantation has significantly improved survival and enhanced the quality of life of patients with end-stage heart failure. Successful long-term outcomes are predicated on a collaborative effort among patients, transplant teams, and primary care providers (PCPs). Notably, PCPs are increasingly pivotal in post-transplant care, engaging in annual assessments, early recognition of complications, and referral, thus minimizing morbidity and mortality. This article highlights key considerations for PCPs, including indications for heart transplant, immunosuppressive therapy and infection prophylaxis, management of post-transplant complications, psychosocial and lifestyle adjustment, and family planning. This roadmap aims to empower PCPs to deliver optimal care and improve long-term outcomes for heart transplant recipients.
- 18 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1346
Open AccessCare of Adult Heart Transplant Recipients by the Primary Care Provider: A Practical Roadmap
Heart transplantation has significantly improved survival and enhanced the quality of life of patients with end-stage heart failure. Successful long-term outcomes are predicated on a collaborative effort among patients, transplant teams, and primary care providers (PCPs). Notably, PCPs are increasingly pivotal in post-transplant care, engaging in annual assessments, early recognition of complications, and referral, thus minimizing morbidity and mortality. This article highlights key considerations for PCPs, including indications for heart transplant, immunosuppressive therapy and infection prophylaxis, management of post-transplant complications, psychosocial and lifestyle adjustment, and family planning. This roadmap aims to empower PCPs to deliver optimal care and improve long-term outcomes for heart transplant recipients.
- 26 April 2022
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 49 (01) , 062-072
To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years
A hypercoagulable state associated with coronavirus disease 2019 (COVID-19) has been well documented and is believed to be strongly supported by a proinflammatory state. The hypercoagulable state in turn results in increased incidence of arterial and venous thromboembolism (VTE) seen in hospitalized COVID-19 when compared with hospitalized non-COVID-19 patient cohorts. Moreover, patients with arterial or VTE and COVID-19 have higher mortality compared with COVID-19 patients without arterial or VTE. Prevention of arterial or VTE thus remains an essential question in the management of COVID-19 patients, especially because of high rates of reported microvascular and macrovascular thrombosis. This has prompted multiple randomized control trials (RCTs) evaluating different anticoagulation strategies in COVID-19 patients at various stages of the disease. Herein, we review findings from RCTs in the past 2 years of antithrombotic therapy in critically ill hospitalized patients, noncritically ill hospitalized patients, patients postdischarge from the hospital, and outpatients. RCTs in critically ill patients demonstrated therapeutic dose anticoagulation does not improve outcomes and has more bleeding than prophylaxis dose anticoagulant in these patients. Trials in noncritically ill hospitalized patients showed a therapeutic dose anticoagulation with a heparin formulation might improve clinical outcomes. Anticoagulation with a direct oral anticoagulant posthospital discharge may improve outcomes, although there is a large RCT in progress. Nonhospitalized COVID-19 patients have an insufficient burden of events to be candidates for antithrombotic therapy. Anticoagulation in pregnant and lactating patients with COVID-19, as well as antiplatelet therapy for COVID-19, is also reviewed. * These authors contributed equally (co-first authors). Publication Date: 25 April 2022 (online) © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 26 April 2022
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 49 (01) , 062-072
To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years
A hypercoagulable state associated with coronavirus disease 2019 (COVID-19) has been well documented and is believed to be strongly supported by a proinflammatory state. The hypercoagulable state in turn results in increased incidence of arterial and venous thromboembolism (VTE) seen in hospitalized COVID-19 when compared with hospitalized non-COVID-19 patient cohorts. Moreover, patients with arterial or VTE and COVID-19 have higher mortality compared with COVID-19 patients without arterial or VTE. Prevention of arterial or VTE thus remains an essential question in the management of COVID-19 patients, especially because of high rates of reported microvascular and macrovascular thrombosis. This has prompted multiple randomized control trials (RCTs) evaluating different anticoagulation strategies in COVID-19 patients at various stages of the disease. Herein, we review findings from RCTs in the past 2 years of antithrombotic therapy in critically ill hospitalized patients, noncritically ill hospitalized patients, patients postdischarge from the hospital, and outpatients. RCTs in critically ill patients demonstrated therapeutic dose anticoagulation does not improve outcomes and has more bleeding than prophylaxis dose anticoagulant in these patients. Trials in noncritically ill hospitalized patients showed a therapeutic dose anticoagulation with a heparin formulation might improve clinical outcomes. Anticoagulation with a direct oral anticoagulant posthospital discharge may improve outcomes, although there is a large RCT in progress. Nonhospitalized COVID-19 patients have an insufficient burden of events to be candidates for antithrombotic therapy. Anticoagulation in pregnant and lactating patients with COVID-19, as well as antiplatelet therapy for COVID-19, is also reviewed. * These authors contributed equally (co-first authors). Publication Date: 25 April 2022 (online) © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA